Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | -0.64 Increased by +58.44% | -0.93 Increased by +31.38% |
| Nov 5, 24 | -1.72 Increased by +40.28% | -1.89 Increased by +8.99% |
| Sep 3, 24 | -2.11 Increased by +2.31% | -1.46 Decreased by -44.52% |
| May 2, 24 | -2.30 Decreased by -16.16% | -1.50 Decreased by -53.33% |
| Feb 7, 24 | -1.54 Increased by +58.38% | -2.03 Increased by +24.14% |
| Nov 7, 23 | -2.88 Increased by +4.95% | -2.38 Decreased by -21.01% |
| Sep 5, 23 | -2.16 Decreased by -47.95% | -2.59 Increased by +16.60% |
| Apr 27, 23 | -1.98 Increased by +10.41% | -2.66 Increased by +25.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 173.92 M Increased by +81.36% | -38.47 M Increased by +70.64% | Decreased by -22.12% Increased by +83.81% |
| Sep 30, 24 | 57.83 M Increased by +20.40% | -99.20 M Increased by +38.85% | Decreased by -171.52% Increased by +49.21% |
| Jun 30, 24 | 36.00 M Decreased by -24.04% | -109.38 M Increased by +9.93% | Decreased by -303.85% Decreased by -18.59% |
| Mar 31, 24 | 36.00 M Increased by +7.17% | -109.38 M Increased by +1.38% | Decreased by -303.85% Increased by +7.98% |
| Dec 31, 23 | 95.89 M Increased by +318.82% | -131.03 M Increased by +36.83% | Decreased by -136.65% Increased by +84.92% |
| Sep 30, 23 | 48.03 M Increased by +214.15% | -162.22 M Increased by +3.98% | Decreased by -337.73% Increased by +69.44% |
| Jun 30, 23 | 47.39 M Increased by +209.96% | -121.43 M Increased by +28.13% | Decreased by -256.23% Increased by +76.81% |
| Mar 31, 23 | 33.59 M Increased by +391.93% | -110.91 M Increased by +11.62% | Decreased by -330.21% Increased by +82.03% |